CMPSCOMPASS Pathways plc

Nasdaq compasspathways.com


$ 6.03 $ 0.10 (1.69 %)    

Tuesday, 02-Jul-2024 10:57:29 EDT
QQQ $ 483.47 $ 3.58 (0.75 %)
DIA $ 391.49 $ 0.65 (0.17 %)
SPY $ 545.81 $ 2.07 (0.38 %)
TLT $ 90.35 $ -0.32 (-0.35 %)
GLD $ 215.15 $ -0.13 (-0.06 %)
$ 5.95
$ 5.93
$ 0.00 x 0
$ 0.00 x 0
$ 5.93 - $ 6.03
$ 5.01 - $ 12.75
315,796
na
382.12M
$ 1.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 02-24-2022 12-31-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cantor-fitzgerald-reiterates-overweight-on-compass-pathways

Cantor Fitzgerald analyst Charles Duncan reiterates Compass Pathways (NASDAQ:CMPS) with a Overweight.

Core News & Articles

https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after...

 whats-going-on-with-mindmed-and-psychedelic-stocks

Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approv...

Core News & Articles

https://www.marijuanamoment.net/top-federal-drug-official-says-theres-tremendous-excitement-around-psych

 hc-wainwright--co-reiterates-buy-on-compass-pathways-maintains-120-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Compass Pathways (NASDAQ:CMPS) with a Buy and maintains $120 pri...

 compass-pathways-reports-q1-cash-and-cash-equivalents-of-2629m

Second quarter 2024 net cash used in operating activities is expected to be in the range of $32 million to $38 million. The ...

 compass-pathways-announced-topline-results-from-an-open-label-phase-2-study-of-comp360-psilocybin-treatment-for-post-traumatic-stress-disorder-the-study-met-its-primary-safety-endpoint-and-available-secondary-efficacy-endpoints

Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clin...

Core News & Articles

https://www.marijuanamoment.net/fda-expert-committee-will-review-mdma-assisted-therapy-for-ptsd-next-month/The Food and Drug Ad...

 compass-pathways-mindful-health-solutions-enter-research-collaboration-agreement-to-inform-development-of--scalable-and-cost-effective-delivery-model-for-comp360-psilocybin-treatment

This is the latest of several collaborations for Compass, intended to better understand a range of potential approaches to deli...

 cantor-fitzgerald-reiterates-overweight-on-compass-pathways

Cantor Fitzgerald analyst Charles Duncan reiterates Compass Pathways (NASDAQ:CMPS) with a Overweight.

 cantor-fitzgerald-reiterates-overweight-on-compass-pathways

Cantor Fitzgerald analyst Charles Duncan reiterates Compass Pathways (NASDAQ:CMPS) with a Overweight.

 cantor-fitzgerald-reiterates-overweight-on-compass-pathways

Cantor Fitzgerald analyst Charles Duncan reiterates Compass Pathways (NASDAQ:CMPS) with a Overweight.